Drugs / F/TAF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03110380 Comparator | Jun 2017 → Dec 2018 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110380 ↗ |
| Route | Oral | “200/25 mg FDC tablet(s) administered orally once daily” NCT03110380 ↗ |